Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

West Pharmaceutical Services Inc Stock Research

WST

375.40USD-0.20(-0.05%)Market Closed
Watchlist

Market Summary

USD375.40-0.20
Market Closed
-0.05%

WST Alerts

  • 2 major insider sales recently.

WST Stock Price

WST RSI Chart

WST Valuation

Market Cap

27.7B

Price/Earnings (Trailing)

53.48

Price/Sales (Trailing)

9.68

EV/EBITDA

36.42

Price/Free Cashflow

69.91

WST Price/Sales (Trailing)

WST Profitability

EBT Margin

22.54%

Return on Equity

19.89%

Return on Assets

14.83%

Free Cashflow Yield

1.43%

WST Fundamentals

WST Revenue

Revenue (TTM)

2.9B

Revenue Y/Y

-2.27%

Revenue Q/Q

5.19%

WST Earnings

Earnings (TTM)

518.7M

Earnings Y/Y

-17.72%

Earnings Q/Q

10.79%

Price Action

52 Week Range

206.19415.73
(Low)(High)

Last 7 days

-4.8%

Last 30 days

-4.6%

Last 90 days

1.7%

Trailing 12 Months

47.7%

WST Financial Health

Current Ratio

3.62

Debt/Equity

0.08

Debt/Cashflow

3.46

WST Investor Care

Dividend Yield

0.19%

Dividend/Share (TTM)

0.74

Buy Backs (1Y)

0.67%

Diluted EPS (TTM)

6.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for WST

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-30
Favorite Annette F
acquired
166,940
83.47
2,000
sr. vp & chief hr officer
2023-08-30
Favorite Annette F
sold
-829,277
414
-2,000
sr. vp & chief hr officer
2023-08-22
Reiss-Clark Cindy
acquired
915,007
263
3,477
chief commercial officer
2023-08-22
Reiss-Clark Cindy
sold
-1,367,640
393
-3,477
chief commercial officer
2023-08-11
Lai Quintin J
sold
-8,337,490
395
-21,101
vp strat & investor relations
2023-08-11
Lai Quintin J
acquired
2,646,110
125
21,101
vp strat & investor relations
2023-08-09
Witherspoon Charles
acquired
231,613
137
1,680
vp & treasurer
2023-08-09
Witherspoon Charles
sold
-666,187
396
-1,680
vp & treasurer
2023-08-08
Green Eric Mark
sold
-17,369,800
394
-44,000
president & ceo
2023-08-08
Abraham Silji
acquired
836,482
102
8,160
svp, chief technology officer

1–10 of 50

Which funds bought or sold WST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
new
-
2,429,790
2,429,790
0.02%
2023-09-21
Baystate Wealth Management LLC
unchanged
-
217
2,301
-%
2023-09-20
BARCLAYS PLC
added
84.93
25,507,000
50,000,000
0.03%
2023-09-12
Farther Finance Advisors, LLC
added
28.25
25,501
86,829
0.02%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
unchanged
-
756
8,032
-%
2023-09-05
Covenant Partners, LLC
unchanged
-
31,788
337,721
0.12%
2023-09-01
Portside Wealth Group, LLC
new
-
1,031,520
1,031,520
0.19%
2023-08-30
Western Wealth Management, LLC
unchanged
-
49,972
530,883
0.04%
2023-08-28
DT Investment Partners, LLC
unchanged
-
227
15,239
-%
2023-08-24
Alberta Investment Management Corp
unchanged
-
671,688
7,136,120
0.07%

1–10 of 48

Latest Funds Activity

Are funds buying WST calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own WST
No. of Funds

Schedule 13G FIlings of West Pharmaceutical Services

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
3.1%
2,301,161
SC 13G/A
Feb 09, 2023
vanguard group inc
12.14%
8,988,409
SC 13G/A
Jan 24, 2023
blackrock inc.
11.0%
8,148,624
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
8.4%
6,241,901
SC 13G/A
Feb 04, 2022
franklin resources inc
3.8%
2,848,869
SC 13G/A
Jan 27, 2022
blackrock inc.
10.9%
8,094,288
SC 13G/A
Jan 25, 2022
blackrock inc.
10.9%
8,094,288
SC 13G/A
Apr 12, 2021
blackrock inc.
10.1%
7,467,809
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
6.2%
4,624,247
SC 13G/A
Feb 10, 2021
vanguard group inc
11.21%
8,289,370
SC 13G/A

Recent SEC filings of West Pharmaceutical Services

View All Filings
Date Filed Form Type Document
Sep 21, 2023
8-K/A
Current Report
Sep 01, 2023
4
Insider Trading
Aug 24, 2023
4
Insider Trading
Aug 15, 2023
4
Insider Trading
Aug 11, 2023
4
Insider Trading
Aug 10, 2023
4
Insider Trading
Aug 10, 2023
4
Insider Trading
Aug 08, 2023
4
Insider Trading
Aug 08, 2023
144
Notice of Insider Sale Intent
Jul 27, 2023
8-K
Current Report

Peers (Alternatives to West Pharmaceutical Services)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
182.5B
30.4B
-1.37% -4.99%
28.7
6.01
-1.49% 0.14%
167.5B
40.2B
-6.47% -2.73%
32.45
4.16
-11.68% -39.67%
105.0B
31.6B
-2.70% -3.25%
28.96
3.33
1.57% -30.40%
35.9B
3.5B
-11.25% 30.83%
45.38
10.22
6.21% 19.20%
27.7B
2.9B
-4.60% 47.73%
53.48
9.68
-2.14% -24.34%
MID-CAP
9.5B
937.8M
-1.70% 33.64%
325.17
10.1
16.30% 250.21%
4.5B
1.1B
-2.64% -5.47%
135.07
4.01
69.36% 3.03%
4.2B
822.4M
-14.46% 31.58%
-184
5.12
56.01% -147.34%
-
-
-7.20% -1.41%
-
-
- -
SMALL-CAP
1.5B
301.6M
2.29% 56.91%
-550.1
4.93
-3.75% -104.51%
1.2B
254.9M
2.45% 31.18%
-62.25
4.89
-1.22% 15.74%
653.5M
240.7M
-3.82% -45.97%
-15.31
2.72
4.82% 85.44%
45.4M
9.0M
48.55% -15.88%
-2.52
5.03
20.81% 50.13%
766.7K
37.4M
-50.00% -99.61%
-0.01
0.02
-2.49% 10.49%

West Pharmaceutical Services News

InvestorsObserver
West Pharmaceutical Services Inc. (WST) Stock: How Does it Score on Valuation Metrics?.
InvestorsObserver,
6 hours ago
Investor's Business Daily
S&P 500: The 12 Stocks Driving The Index Higher In 2023.
Investor's Business Daily,
27 hours ago
Best Stocks
InvestorPlace
Yahoo Finance

Returns for WST

Cumulative Returns on WST

25.4%


10-Year Cumulative Returns

27.1%


7-Year Cumulative Returns

25.5%


5-Year Cumulative Returns

11.8%


3-Year Cumulative Returns

Risks for WST

What is the probability of a big loss on WST?

66.9%


Probability that West Pharmaceutical Services stock will be more than 20% underwater in next one year

27.3%


Probability that West Pharmaceutical Services stock will be more than 30% underwater in next one year.

11.5%


Probability that West Pharmaceutical Services stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does WST drawdown profile look like?

Y-axis is the maximum loss one would have experienced if West Pharmaceutical Services was unfortunately bought at previous high price.

Drawdowns

Financials for West Pharmaceutical Services

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-0.6%2,8662,8842,8872,9092,9292,8812,8322,6812,5232,3262,1472,0371,9451,8881,8401,7921,7671,7451,7171,7111,677
Gross Profit-2.7%1,0931,1231,1361,1751,1951,1891,1761,086993873768710663626606586574558545541530
  S&GA Expenses2.2%326320317329355366363341325310302295283276273263264263263263261
  R&D Expenses3.4%63.0061.0059.0056.0056.0055.0053.0052.0051.0048.0047.0044.0041.0040.0039.0039.0039.0041.0040.0040.0039.00
EBITDA-100.0%-777805861906893879806721607519475442420404393-----
EBITDA Margin-100.0%-0.27*0.28*0.30*0.31*0.31*0.31*0.30*0.29*0.26*0.24*0.23*0.23*0.22*0.22*0.22*-----
Interest Expenses11.4%9.008.008.009.008.009.008.008.008.008.008.008.008.008.009.009.009.009.008.008.008.00
Earnings Before Taxes-6.5%608650680733778762749682599490401364331308292280276257241234236
EBT Margin-100.0%-0.23*0.24*0.25*0.27*0.26*0.26*0.25*0.24*0.21*0.19*0.18*0.17*0.16*0.16*0.16*-----
Net Income-6.0%519552586631686684662613519423346312286261242230229219207155151
Net Income Margin-100.0%-0.19*0.20*0.22*0.23*0.24*0.23*0.23*0.21*0.18*0.16*0.15*0.15*0.14*0.13*0.13*-----
Free Cashflow-100.0%-410439388402382331337284307298276281247241215-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-1.5%3,6703,7243,6173,3173,3623,2953,3143,1432,9342,7402,7942,5832,3922,2472,3412,1742,1232,0361,9791,9461,874
  Current Assets-3.3%1,8741,9371,9201,7341,7711,6911,7421,5981,4771,3271,3741,2381,1119781,0591,004944868894850767
    Cash Equivalents-10.2%796886894729719668763688576484616519446335439396327266337297226
  Inventory0.5%449447415413412417378354345310321295275251236230232226215207208
  Net PPE3.8%1,2611,2151,1581,0691,0771,0661,0581,007973931943883840828839812823815822822827
  Goodwill0.2%108108107104107109110109110110111109108107108107108105106106107
Liabilities-2.6%923947932846937969978940901911939864786756768686678667583594592
  Current Liabilities-4.4%512535519457565585594559473483503448375344342335313301284289288
    LT Debt, Non Current-0.2%206206207207208208209210252252253253254254255195196196196196196
Shareholder's Equity-1.1%2,7472,7762,6852,4712,4242,3262,3352,2022,0331,8291,8551,7191,6061,4901,5731,4881,4451,3701,3961,3521,282
  Retained Earnings4.5%3,2553,1142,9882,9132,7932,6172,4572,3362,1601,9851,8471,7731,7031,6121,5491,4971,4531,3981,3531,3131,258
  Additional Paid-In Capital-12.8%158181232231225220249251248247267268263268273269273279282283305
Accumulated Depreciation1.4%1,2821,2641,2281,1641,1691,1711,1581,1401,1251,0981,0921,0561,018989981968964945931924910
Shares Outstanding-0.4%74.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-0.5%707711724654675647584572500504473430420377367334314291289297284
  Share Based Compensation7.5%29.0027.0024.0027.0032.0037.0038.0034.0033.0035.0034.0033.0029.0024.0024.0019.0019.0018.0015.0017.0017.00
Cashflow From Investing-5.3%-318-302-288-270-277-266-253-233-217-202-179-242-225-231-228-136-130-100-100-101-109
Cashflow From Financing-73.3%-332-191-293-290-220-184-168-170-172-173-137-77.40-70.60-66.60-36.80-96.00-85.50-114-80.70-159-172
  Dividend Payments1.8%56.0055.0054.0053.0052.0052.0051.0050.0050.0049.0048.0047.0047.0046.0045.0044.0044.0043.0042.0041.0041.00
  Buy Backs125.0%26111620320317614713713713713711611611611683.0083.0083.0010671.00118118

WST Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Net sales$ 753.8$ 771.3$ 1,470.4$ 1,491.3
Cost of goods and services sold462.4449.8907.7885.2
Gross profit291.4321.5562.7606.1
Research and development16.514.433.629.0
Selling, general and administrative expenses88.481.5174.4164.9
Other expense (income) (Note 15)4.0(2.8)16.9(5.9)
Operating profit182.5228.4337.8418.1
Interest expense, net2.71.84.94.0
Interest income(5.0)(0.4)(9.8)(0.7)
Other nonoperating (income) expense(0.1)(0.2)(0.1)(0.2)
Income before income taxes and equity in net income of affiliated companies184.9227.2342.8415.0
Income tax expense34.844.258.465.4
Equity in net income of affiliated companies(5.0)(5.5)(10.7)(12.7)
Net income$ 155.1$ 188.5$ 295.1$ 362.3
Net income per share:    
Basic (in dollars per share)$ 2.08$ 2.53$ 3.96$ 4.87
Diluted (in dollars per share)$ 2.06$ 2.48$ 3.91$ 4.77
Weighted average shares outstanding:    
Basic (in shares)74.374.474.474.4
Diluted (in shares)75.475.875.575.9

WST Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 796.3$ 894.3
Accounts receivable, net534.4507.4
Inventories449.4414.8
Other current assets94.1103.0
Total current assets1,874.21,919.5
Property, plant and equipment2,543.32,386.6
Less: accumulated depreciation and amortization1,282.01,228.3
Property, plant and equipment, net1,261.31,158.3
Operating lease right-of-use assets99.2104.4
Investments in affiliated companies202.8204.9
Goodwill108.0107.3
Intangible assets, net16.818.4
Deferred income taxes67.065.6
Other noncurrent assets40.338.4
Total Assets3,669.63,616.8
Current liabilities:  
Notes payable and other current debt2.22.2
Accounts payable218.0215.4
Accrued salaries, wages and benefits85.476.8
Income taxes payable26.724.8
Operating lease liabilities16.216.0
Other current liabilities163.1183.8
Total current liabilities511.6519.0
Long-term debt205.6206.7
Deferred income taxes15.414.3
Pension and other postretirement benefits27.328.2
Operating lease liabilities87.393.0
Deferred compensation benefits20.619.1
Other long-term liabilities55.151.6
Total Liabilities922.9931.9
Commitments and contingencies
Equity:  
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding0.00.0
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: 75.3 million and 75.3 million; shares outstanding: 73.9 million and 74.1 million18.818.8
Capital in excess of par value158.2232.2
Retained earnings3,254.62,987.8
Accumulated other comprehensive loss(183.5)(183.0)
Treasury stock, at cost (1.4 million and 1.2 million shares)(501.4)(370.9)
Total Equity2,746.72,684.9
Total Liabilities and Equity$ 3,669.6$ 3,616.8
Eric M. Green
10100
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.